Dr Björsne graduated at the University of Lund in 1989 and took his post graduate studies at Stockholm University where he did his PhD on Medicinal Chemistry targeting the HIV protease enzyme. Dr Björsne joined Astra Hassle in 1995 and worked in the preclinical Cardiometabolic unit. From his period in this field Dr. Björsne is the inventor of a series of compounds which have advanced to phase 2 clinical trials.
After holding a series of managerial positions within the Cardiovascular Discovery Research Management, Dr Björsne moved to the Strategic Planning & Business Development organisation in 2006 where he has been leading the Cardiovascular Business Development team involved in the search, evaluation and transaction of M&As and licensing deals. Since 2014 Dr Björsne is leading AZ BioVentureHub – a novel approach to open innovation which allows smaller Biotechs and academic groups to work in close proximity to the skills and capabilities that resides within big pharma.